1,721,431 research outputs found
Griffiths, Gareth. Interview about the Fowler House in Brigus.
No full textMegan Webb interviews Gareth Griffiths about his knowledge of previous ownership of Fowler House as well as his own ownership and changes he made to the Fowler House in Brigus.0:00 Beginning of recording; 0:08 Hello; 0:56 Introduction; 1:26 His childhood memories of Fowler House; 2:05 Richard Fowler; 2:29 Richard and Sadie Fowler; 2:40 John Fowler (Richard’s Father); 2:55 Fowlers had foster children; 3:36 Bought house in 2010; 3:53 Terrance Burke; 4:20 Thomas Burke; 6:00 Exterior renovations conversation with current owner; 6:30 Maintenance/changes he made to house; 9:01 Changes made prior to his ownership; 10:25 Plumbing; 11:13 Rich and Sadie; 12:00 Richard Fowler; 14:00 Memories from ownership; 15:10 Fowler House iconic to Brigus; 16:48 Historic photograph; 17:56 Front deck higher than road; 19:25 Realtor photographs with Realestate Board; 24:33 End recording
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply
No full textInterferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators
No full textBACKGROUND: Metastatic renal carcinoma has a 2-year survival of around 20% and is largely resistant to chemotherapy. The use of interferons in the treatment of metastatic renal carcinoma remains controversial. Although non-randomised studies suggest that biological therapy with interferons produces a small number of tumour responses, most clinicians judge such treatment to be ineffective. We have investigated the effect of treatment with interferon-alpha on survival in patients with metastatic renal carcinoma.METHODS: In a multicentre, randomised trial, patients with metastatic renal carcinoma were randomly assigned subcutaneous interferon-alpha (three doses--5 MU, 5 MU, 10 MU--for the first week, then 10 MU three times per week for a further 11 weeks; n=174) or oral medroxyprogesterone acetate (MPA; 300 mg once daily for 12 weeks; n=176). The primary endpoint was overall survival. Analysis was by intention to treat. The trial used a triangular sequential design for early termination as soon as results were conclusive. The trial was stopped in November, 1997, when data were available for 335 patients (167 interferon-alpha, 168 MPA).FINDINGS: A total of 111 patients have died in the interferon-alpha group, and 125 patients have died in the MPA group. There was a 28% reduction in the risk of death in the interferon-alpha group (hazard ratio 0.72 [95% CI 0.55-0.94], p=0.017). Interferon-alpha gave an improvement in 1-year survival of 12% (MPA 31% survival, interferon-alpha 43%), and an improvement in median survival of 2.5 months (MPA 6 months, interferon-alpha 8.5 months).INTERPRETATION: The benefit of treatment with interferon-alpha should be weighed against the drug's toxic effects. Combination regimens of biological therapy and chemotherapy should now be compared with interferon-alpha monotherapy in randomised controlled trials.</p
Clinical trials in oncology
No full textThe development of a new treatment in cancer generally involves its assessment in Phase I, II and III prospective clinical trials. This article gives an overview of these phases of clinical trials, through which almost every new treatment must pass on the journey from its discovery in the laboratory to its routine use in clinical practice. The aim of the Phase I trial is to establish a dose, that of Phase II to evaluate activity, safety and feasibility, and that of Phase III to compare the new treatment against a suitable comparator
An open-source SQL database schema for integrated clinical and translational data management in clinical trials
No full textUnlocking the power of personalised medicine in oncology hinges on the integration of clinical trial data with translational data (i.e. biospecimen-derived molecular information). This combined analysis allows researchers to tailor treatments to a patient's unique biological makeup. However, current practices within UK Clinical Trials Units present challenges. While clinical data are held in standardised formats, translational data are complex, diverse, and requires specialised storage. This disparity in format creates significant hurdles for researchers aiming to curate, integrate and analyse these datasets effectively. This article proposes a novel solution: an open-source SQL database schema designed specifically for the needs of academic trial units. Inspired by Cancer Research UK's commitment to open data sharing and exemplified by the Southampton Clinical Trials Unit's CONFIRM trial (with over 150,000 clinical data points), this schema offers a cost-effective and practical 'middle ground' between raw data and expensive Secure Data Environments/Trusted Research Environments. By acting as a central hub for both clinical and translational data, the schema facilitates seamless data sharing and analysis. Researchers gain a holistic view of trials, enabling exploration of connections between clinical observations and the molecular underpinnings of treatment response. Detailed instructions for setting up the database are provided. The open-source nature and straightforward design ensure ease of implementation and affordability, while robust security measures safeguard sensitive data. We further showcase how researchers can leverage popular statistical software like R to directly query the database. This approach fosters collaboration within the academic discovery community, ultimately accelerating progress towards personalised cancer therapies
- …
